Serum Source International, Inc.

serumsourceintl.com

Serum Source International is a private, certified small business, located in Charlotte, North Carolina, USA. Established in 2006, Serum Source International acquired U.S. Bio-Technologies, a Pennsylvania based company leading in global wholesale distribution of sera, media and reagents to the cell culture industry, operating since 1999.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PALO ALTO-BASED BIOTECH STARTUP TO MASS MANUFACTURE CLINICAL-GRADE IPSCS FOR CELL THERAPY

I Peace, Inc. | July 16, 2020

news image

I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette. The system was developed in collaboration with FANUC CORPORATION (Head Office: Oshino, Yamanashi Prefecture, Japan; CEO: Kenji Yamaguchi). The technology is modular and scalable with a small foot...

Read More

Medical

IMMUNIC REPORTS POSITIVE INTERIM DATA FROM PHASE 2 CALLIPER TRIAL OF VIDOFLUDIMUS CALCIUM IN PROGRESSIVE MULTIPLE SCLEROSIS

PR Newswire | October 10, 2023

news image

Immunic, Inc. a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). The Company believes t...

Read More

Industrial Impact

BIOCYTOGEN AND LIBEROTHERA ACHIEVE MILESTONE PROGRESS IN CO-DEVELOPMENT OF FULLY HUMAN GPCR ANTIBODY DRUGS

Biocytogen | July 21, 2022

news image

Biocytogen Pharmaceuticals Co., Ltd. entered a strategic collaboration with LiberoThera Co., Ltd to co-develop fully human GPCR antibodies using Biocytogen’s advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoThera’s outstanding membrane antigen preparation technology. In around a year since the collaboration was established, the two parties have screened out a number of fully human therapeutic antibody clones with excellent anti-tumo...

Read More

US BIOTECH FIRM DONATING 1.5 MILLION DOSES OF EXPERIMENTAL CORONAVIRUS DRUG

TheHill | April 05, 2020

news image

Gilead Sciences Inc., a U.S. biotechnology firm that develops and commercializes drugs, has rapidly expanded its supply of an experimental coronavirus drug and is prepared to donate 1.5 million doses of it to hospitals dealing with severely ill patients. Gilead CEO Daniel O'Day said in a statement Saturday that the 1.5 million doses of the drug, known as remdesivir, could be part of treatment courses for as many as 140,000 patients. He said the doses were available for "compassionate us...

Read More
news image

PALO ALTO-BASED BIOTECH STARTUP TO MASS MANUFACTURE CLINICAL-GRADE IPSCS FOR CELL THERAPY

I Peace, Inc. | July 16, 2020

I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette. The system was developed in collaboration with FANUC CORPORATION (Head Office: Oshino, Yamanashi Prefecture, Japan; CEO: Kenji Yamaguchi). The technology is modular and scalable with a small foot...

Read More
news image

Medical

IMMUNIC REPORTS POSITIVE INTERIM DATA FROM PHASE 2 CALLIPER TRIAL OF VIDOFLUDIMUS CALCIUM IN PROGRESSIVE MULTIPLE SCLEROSIS

PR Newswire | October 10, 2023

Immunic, Inc. a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). The Company believes t...

Read More
news image

Industrial Impact

BIOCYTOGEN AND LIBEROTHERA ACHIEVE MILESTONE PROGRESS IN CO-DEVELOPMENT OF FULLY HUMAN GPCR ANTIBODY DRUGS

Biocytogen | July 21, 2022

Biocytogen Pharmaceuticals Co., Ltd. entered a strategic collaboration with LiberoThera Co., Ltd to co-develop fully human GPCR antibodies using Biocytogen’s advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoThera’s outstanding membrane antigen preparation technology. In around a year since the collaboration was established, the two parties have screened out a number of fully human therapeutic antibody clones with excellent anti-tumo...

Read More
news image

US BIOTECH FIRM DONATING 1.5 MILLION DOSES OF EXPERIMENTAL CORONAVIRUS DRUG

TheHill | April 05, 2020

Gilead Sciences Inc., a U.S. biotechnology firm that develops and commercializes drugs, has rapidly expanded its supply of an experimental coronavirus drug and is prepared to donate 1.5 million doses of it to hospitals dealing with severely ill patients. Gilead CEO Daniel O'Day said in a statement Saturday that the 1.5 million doses of the drug, known as remdesivir, could be part of treatment courses for as many as 140,000 patients. He said the doses were available for "compassionate us...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy

VIA Thaw™ automated dry thawer

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us